Drug updated on 4/16/2024
| Dosage Form | Solution (topical: 5%) |
| Drug Class | Oxaborole antifungals |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.
Summary
- Tavaborole (Kerydin) is indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.
- Two studies were reviewed, providing a comparative analysis between Kerydin and other antifungal treatments such as Efinaconazole, Ciclopirox, P-3051, and device-based therapies like 1064-nm Nd:YAG laser.
- In terms of effectiveness, Tavaborole has moderate to high-quality evidence supporting its use. It appears superior in efficacy compared to ciclopirox lacquer but slightly less effective than efinaconazole based on complete cure rates.
- Regarding safety profile comparison; both efinaconazole and Tavaborole have higher incidences of minor adverse events compared to control treatments. However, these are generally localized application site reactions, which are considered safer than oral treatments that require closer monitoring due to systemic side effects.
- The studies covered a wide age range from 27 to 68 years, suggesting applicability across a broad adult population. Most studies focused on mild-to-moderate cases without matrix involvement, limiting their applicability for severe cases involving the nail matrix directly.
- While the primary focus was on dermatophyte-caused onychomycosis mainly by Trichophyton species, considerations for causative organism specificity in treatment choice were emphasized, especially where effectiveness might vary based on the fungal species involved.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Kerydin (tavaborole) Prescribing Information. | 2018 | Pfizer Labs, Division of Pfizer Inc., NY, NY 10017 |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Topical and device-based treatments for fungal infections of the toenails (review). | 2020 | Cochrane Database of Systematic Reviews |
| Antifungal drug use for onychomycosis. | 2019 | American Journal of Therapeutics |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Therapeutic recommendations for the treatment of toenail onychomycosis in the US. | 2021 | Journal of Drugs in Dermatology |